The Multigene Signature MammaPrint Impacts on Multidisciplinary Team Decisions in ER+, HER2− Early Breast Cancer

PUBLICATION: British Journal of Cancer, volume 111, pages 837–842 (26 Read More

2024-03-25T10:20:39-04:00August 26th, 2014|Adjuvant, Evidence, MammaPrint|

Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

PUBLICATION: Annals of Surgical Oncology; October 2014, Volume 21, Issue Read More

2024-02-20T10:41:05-05:00August 7th, 2014|Evidence, NBRST, Neoadjuvant|

Optimized Outcome Prediction in Breast Cancer by Combining the 70-Gene Signature with Clinical Risk Prediction Algorithms

PUBLICATION: Breast Cancer Res Treat. 2014 Jun;145(3):697-705. doi: 10.1007/s10549-014-2954-2. Epub Read More

2024-03-25T10:21:40-04:00June 1st, 2014|Adjuvant, Evidence, MammaPrint, RASTER|

Risk Estimations and Treatment Decisions in Early Stage Breast Cancer: Agreement Among Oncologists and the Impact of the 70-Gene Signature

PUBLICATION: Eur J Cancer. 2014 Apr;50(6):1045-54. doi: 10.1016/j.ejca.2014.01.016. Epub 2014 Read More

2024-03-25T10:23:07-04:00April 1st, 2014|Adjuvant, Evidence, MammaPrint, RASTER|
Go to Top